PetCaseFinder

Peer-reviewed veterinary case report

Long-term stem cell treatment for dog rheumatoid arthritis

By Seo, Min-Gyeong et al.·Published in Journal of veterinary science·2022·Department of Veterinary Pathology, South Korea·View original on PubMed

PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →

Original publication title: Long-term treatment of allogeneic adipose-derived stem cells in a dog with rheumatoid arthritis.

Species:
dog

Plain-English summary

A dog with rheumatoid arthritis, a rare condition that causes joint pain and inflammation, received monthly injections of stem cells from healthy donors for 11 months. The treatment aimed to reduce inflammation and improve the dog's overall condition. After the treatment, the dog's joint health improved significantly, and there were no side effects from the injections. The owner was very satisfied with the results, indicating that this long-term stem cell therapy could be a promising option for managing rheumatoid arthritis in dogs.

People also search for: dog rheumatoid arthritis treatment · stem cell therapy for dogs · joint pain in dogs · dog arthritis injections

Abstract

BACKGROUND: Although there are growing demands for stem cell-based therapy for companion animals in various diseases, a few clinical trials have been reported. Moreover, most of them are the results from only one or a few times of stem cell injection. OBJECTIVES: The aim of this study is to describe a long-term treatment with allogeneic adipose-derived stem cells (ASCs) in a dog with rheumatoid arthritis (RA), which is a rare canine disease. METHODS: The dog with RA received intravascular injection of allogeneic ASCs derived from two healthy donors once a month for 11 months. To assess therapeutic effects of ASCs, orthopedic examination and clinical evaluation was performed. Cytokines of tumor necrosis factor-α and interleukin-6 in the plasma were measured using ELISA analysis. RESULTS: Despite this repeated and long-term administration of allogeneic ASCs, there were no side effects such as immunorejection responses or cell toxicity. The orthopedic examination score for the dog decreased after ASCs treatment, and the clinical condition of the dog and owner's satisfaction were very good. CONCLUSIONS: Although ASCs has been suggested as one of the options for RA treatment because of its anti-inflammatory and immunosuppressive functions, it has never been used to treat RA in dogs. The present report describes a case of canine RA treated with allogeneic ASCs for long-term in which the dog showed clinical improvement without adverse effects.

Find similar cases for your pet

PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.

Search related cases →

Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/35920125/